EXOZYMES INC
EXOZNASDAQTrading Snapshot
- Day Range
- $6.08 – $6.16
- 52-Week Range
- $4.35 – $18.40
- Volume
- $3.27B
- Avg Volume
- $3.42B
- Shares Outstanding
- 9.3M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $970,991
- P/E Ratio
- -5.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.18
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.1%
Why Investors Own EXOZ
- ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EXOZYMES INC
EXOZ
StockOtter · stockotter.spaceAbout EXOZYMES INC
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of A
eXoZymes Q2 Earnings Call Highlights
eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundan
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has fallen more than 10
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, Au